The correlation between FUBP1 and the clinical pathological stage was analyzed using GEPIA2, and the results (medians and p values) showed that the expression of FUBP1 was positively correlated with the cancer stage from stage I to stage III in LIHC and from stage 0 to stage I and from stage II to III in SKCM (skin cutaneous melanoma), while it was negatively correlated with the clinical stage in OV (p < 0.001) (Figure 1D) but not in other cancer types (Supplementary Figures S4B–E). Here, FUBP1 is linked to cutaneous melanoma.